Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO)

Basit Öğe Kaydı
dc.authoridbenekli, mustafa/0000-0003-3184-4946
dc.authoridOzturk, Banu/0000-0003-0290-8787
dc.authoridÖksüzoğlu Çakmak, Ömür Berna/0000-0002-2756-8646
dc.authoridUlas, Arife/0000-0003-2918-2592
dc.authoridSevinç, Alper/0000-0002-0499-8918
dc.authoridharputluoglu, hakan/0000-0001-8537-5941
dc.authoridKaplan, Muhammet Ali/0000-0003-0882-0524
dc.authorwosidBerk, Veli/IXE-0017-2023
dc.authorwosidbenekli, mustafa/AAE-4555-2020
dc.authorwosidOzturk, Banu/AAD-4358-2019
dc.authorwosidSevinc, Alper/KFQ-6440-2024
dc.authorwosidÖksüzoğlu Çakmak, Ömür Berna/HKN-6428-2023
dc.authorwosidUlas, Arife/HGD-4686-2022
dc.authorwosidSevinç, Alper/KPA-4519-2024
dc.contributor.authorCetin, Bulent
dc.contributor.authorBenekli, Mustafa
dc.contributor.authorTurker, Ibrahim
dc.contributor.authorKoral, Lokman
dc.contributor.authorUlas, Arife
dc.contributor.authorDane, Faysal
dc.contributor.authorOksuzoglu, Berna
dc.date.accessioned2024-08-04T20:39:58Z
dc.date.available2024-08-04T20:39:58Z
dc.date.issued2014
dc.departmentİnönü Üniversitesien_US
dc.description.abstractLapatinib is the first dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2/neu) and epidermal growth factor receptor (EGFR). The present study evaluated the efficacy and tolerability of the combination of lapatinib and capecitabine in patients with metastatic breast cancer (MBC) who progressed after therapy with trastuzumab, a taxane and/or anthracycline. A total of 203 patients with a median age of 48 years (range: 25-82 years) were evaluated retrospectively in 11 centres between September 2007 and May 2011. All the patients had HER2-positive MBC progressing after trastuzumab and chemotherapy including an anthracycline and/or taxane. All patients were treated with the combination of lapatinib (1250 mg/day, continuously) and capecitabine (2000 mg/m(2) on days 1 through 14 of a 21-day cycle). Data on demographics, clinical outcome, and toxicity were collected for descriptive analyses. The median follow-up was 10.7 months (range: 1-40 months). An overall response rate (ORR) of 33.4% was achieved including 7 complete responses (CR, 3.4%), 61 partial responses (PR, 30.0%), and 44 stable disease (37.9%). Clinical benefit rate of 71.3% was achieved. Median progression-free survival (PFS) was 7 months (95% CI: 6-10 months), with a median overall survival (OS) of 15 months (95% CI: 12-18 months). The most common side effects were hand-foot syndrome (46.8%), nausea (42.3%), fatigue (42.2%), anorexia (38.5%), diarrhea (31.5%), and rash (29.6%). Grade 3-4 toxicities were identified as hand foot syndrome (7.9%), diarrhea (6.9%), fatigue (5.9%), and rash (5.4%). There were no symptomatic cardiac events. Lapatinib and capecitabine combination therapy is effective and well tolerated in patients with MBC who had progressive disease after trastuzumab, taxane, and/or anthracycline therapy, as evidenced by this retrospective evaluation. Toxicity was mild to moderate with low grade 3-4 toxicity.en_US
dc.identifier.doi10.1179/1973947813Y.0000000147
dc.identifier.endpage305en_US
dc.identifier.issn1120-009X
dc.identifier.issn1973-9478
dc.identifier.issue5en_US
dc.identifier.pmid24112786en_US
dc.identifier.scopus2-s2.0-84914099751en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage300en_US
dc.identifier.urihttps://doi.org/10.1179/1973947813Y.0000000147
dc.identifier.urihttps://hdl.handle.net/11616/96616
dc.identifier.volume26en_US
dc.identifier.wosWOS:000342075100007en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal of Chemotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdvanced breast canceren_US
dc.subjectLapatiniben_US
dc.subjectCapecitabineen_US
dc.subjectHER2en_US
dc.titleLapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu